ARN-509

Known as: Androgen Receptor Antagonist ARN-509 
A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
0246820102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Purpose: To evaluate the efficacy of apalutamide before or after treatment with abiraterone acetate and prednisone (AAP) in… (More)
Is this relevant?
2016
2016
BACKGROUND Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Activation of androgen receptor (AR) is crucial for prostate cancer growth. Remarkably, also castration-resistant prostate cancer… (More)
Is this relevant?
2014
2014
Androgens are key factors involved in the development and progression of prostate cancer (PCa), and PCa growth can be suppressed… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
UNLABELLED Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC… (More)
Is this relevant?
2013
2013
7 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the androgen… (More)
Is this relevant?
2013
2013
48 Background: ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Continued reliance on the androgen receptor (AR) is now understood as a core mechanism in castration-resistant prostate cancer… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Nicola J. Clegg, John Wongvipat, Jim Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D. Bischoff , Ling… (More)
  • table 1
  • figure 1
Is this relevant?